Avalo Therapeutics

AVTX (NasdaqCM)

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing IL-1β–targeted therapies for immune-mediated inflammatory diseases in the United States. Its lead product, AVTX-009, is a humanized monoclonal antibody that binds interleukin-1β and is in phase 2 trials for inflammatory conditions. Formerly Cerecor Inc., it was renamed Avalo in August 2021. Incorporated in 2011, it is based in Wayne, Pennsylvania.